Author

Mark Lowenberg

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Mark Lowenberg  et al.

BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Mark Lowenberg  et al.

AURICULAR TRANSCUTANEOUS STIMULATION AS AN EXPLORATORY PREOPERATIVE SCREENING TEST FOR CLINICAL RESPONSE TO VAGUS NERVE STIMULATION IN DRUG-RESISTANT CROHN’S DISEASE
AURICULAR TRANSCUTANEOUS STIMULATION AS AN EXPLORATORY PREOPERATIVE SCREENING TEST FOR CLINICAL RESPONSE TO VAGUS NERVE STIMULATION IN DRUG-RESISTANT CROHN’S DISEASE

Mark Lowenberg  et al.

PERIPHERAL BLOOD DNA METHYLATION PROFILES PREDICT RESPONSE TO USTEKINUMAB AND SHOW STABILITY DURING BOTH INDUCTION AND MAINTENANCE TREATMENT IN CROHN’S DISEASE
PERIPHERAL BLOOD DNA METHYLATION PROFILES PREDICT RESPONSE TO USTEKINUMAB AND SHOW STABILITY DURING BOTH INDUCTION AND MAINTENANCE TREATMENT IN CROHN’S DISEASE

Mark Lowenberg  et al.

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL
EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

Mark Lowenberg  et al.

THE NLRP3 INFLAMMASOME IS UPREGULATED ON MRNA EXPRESSION LEVEL AND ACTIVATED ON PROTEIN LEVEL IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A SYSTEMATIC META-ANALYSIS AND IN A NEW OBSERVATIONAL STUDY COHORT
THE NLRP3 INFLAMMASOME IS UPREGULATED ON MRNA EXPRESSION LEVEL AND ACTIVATED ON PROTEIN LEVEL IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A SYSTEMATIC META-ANALYSIS AND IN A NEW OBSERVATIONAL STUDY COHORT

Mark Lowenberg  et al.

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Mark Lowenberg  et al.

INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY
INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY

Mark Lowenberg  et al.

IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Mark Lowenberg  et al.

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS
REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

Mark Lowenberg  et al.

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Mark Lowenberg  et al.

HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB
HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB

Mark Lowenberg  et al.

REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE
REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE

Mark Lowenberg  et al.

MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL
MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL

Mark Lowenberg  et al.

RESPONSE TO TOFACITINIB IN ULCERATIVE COLITIS PREDICTED BY A MACHINE-LEARNING ALGORITHM; A MULTI-OMICS APPROACH
RESPONSE TO TOFACITINIB IN ULCERATIVE COLITIS PREDICTED BY A MACHINE-LEARNING ALGORITHM; A MULTI-OMICS APPROACH

Mark Lowenberg  et al.

Item 1 - 15 / 15
1